Related Experiment Videos
Twenty-four hour variations of thyroid hormones and thyrotrophin concentrations in hypothyroid infants treated with
Insights
For infants with congenital hypothyroidism, levothyroxine (L-T4) treatment shows stable T4 levels. Free T4 (FT4) and TSH levels fluctuate post-dose, impacting monitoring strategies.
Area of Science:
- Pediatric Endocrinology
- Thyroid Hormone Replacement Therapy
Background:
- Congenital hypothyroidism (CH) requires lifelong thyroid hormone replacement.
- Levothyroxine (L-T4) is the standard treatment for CH.
- Understanding the pharmacokinetic profile of L-T4 in infants is crucial for optimal dosing and monitoring.
Purpose of the Study:
- To characterize the 24-hour plasma profiles of thyroid hormones (T4, FT4, T3) and TSH in infants with CH treated with L-T4.
- To assess the impact of a single daily L-T4 dose on these hormone levels.
- To provide guidance on optimal timing for blood sampling in CH monitoring.
Main Methods:
- A group of infants diagnosed with CH received a single daily oral dose of L-T4 (5-7.5 mcg/kg) at 0800h.
- Plasma samples were collected over 24 hours to measure T4, FT4, T3, and TSH concentrations.
- Statistical analysis was performed to determine significant changes and trends in hormone levels post-administration.
Main Results:
- Plasma T4 levels remained relatively constant throughout the 24-hour study period.
- Serum FT4 levels showed a significant increase, peaking at 4 hours post-L-T4 dose.
- Plasma T3 levels significantly decreased 6 hours after medication, while TSH levels also significantly decreased 6 hours post-dose.
Conclusions:
- No specific timing is required for T4 sampling in infants treated for CH with L-T4.
- TSH measurements taken 4-8 hours after L-T4 administration may underestimate mean levels.
- FT4 monitoring requires consideration of post-dose absorption variations for accurate interpretation.
Abstract:
The 24 hour plasma profile of T4, FT4, T3 and TSH was measured in a group of infants treated for congenital hypothyroidism with an oral aqueous preparation of L-T4 (5-7.5 micrograms/kg) given as a single dose at 0800 h. Mean basal plasma T4 was 8.4 +/- 2.0 micrograms/dl (mean +/- SD) and remained constant during the study while mean serum FT4 increased significantly from 1.64 +/- 0.50 ng/dl to a maximum of 2.08 +/- 0.63 ng/dl 4 h after medication. Plasma T3 decreased significantly from 241 +/- 48 ng/dl to 202 +/- 36 ng/dl 6 h after drug administration. Finally, plasma TSH decreased significantly from a mean of 24.2 +/- 18.8 microU/ml to 14.8 +/- 10.5 microU/ml 6 h later. Therefore during treatment of congenital hypothyroidism with L-T4 no specific schedule for T4 sampling is required. However, TSH determination 4 to 8 h after medication could slightly underestimate mean levels. In addition, any attempt to monitor treatment by FT4 determination should take into consideration variations of plasma values in the hours following L-T4 absorption.